Enduring efficacy and tolerability of daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (GEN503): final results of an open-label, phase 1/2 study

Note: Funding Information: All authors developed the manuscript, provided final submission approval and confirmed that the protocol was followed and that the data were accurate and complete. This study was sponsored by Janssen Research and Development. Medical writing and editorial support were provided by Kimberly Carmony, PhD, of MedErgy, and were funded by Janssen Global Services, LLC. The authors thank the patients who participated in this study and their families, as well as the study co-investigators, research nurses and coordinators at each of the clinical sites. Results of this analysis were presented, in part, at the 59th American Society of Hematology (ASH) Annual Meeting & Exposition, December 9–12, 2017, Atlanta, GA, USA. The data sharing policy of Janssen Pharmaceutical Companies of Johnson & Johnson is available at https://www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at http://yoda.yale.edu.